SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 6 Change in serum alanine aminotransferase levels in individual studies

Study	Serum ALT level (IU/L)			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	64.3 (20.2)	49.7 (25.8)	0.001	0.005
	Control	65.3 (40.3)	61.6 (38.4)	0.422
Ito et al[12]	Ipragliflozin	57.4 (27.3)	38.2 (20.5)	< 0.05	0.642
	Pioglitazone	53.1 (26.6)	36.8 (15.1)	< 0.05
Shibuya et al[13]	Luseogliflozin	49.5 (31.0, 70.0)	31 (26.0, 55.0)	0.057	0.064
	Metformin	39 (23.0, 56.0)	39 (27.0, 51.0)	0.518
Eriksson et al[14]	Placebo	33.53 (12.4)	-0.2 (8.8)1	-	-
	Omega-3 CA	37.65 (14.7)	+5.9 (16.5)1	-	Non-significant2
	Dapagliflozin	39.41 (14.7)	-8.2 (8.2)1	-	< 0.052
	O + D	35.88 (17.1)	+0.1 (12.9)1	-	Non-significant2
Ohki et al[15]	Ipragliflozin	62 (43.0-75.0)	38.0 (31.0-65.0)	0.01	-
Seko et al[16]	SGLT-2 inhibitor	70.8 (8.1)	48.8 (5.5)	0.002	0.039
	Sitagliptin	92.4 (11.2)	71.1 (10.0)	0.012
Gautam et al[17]	Canagliflozin	96 (18.7)	60.0 (17.6)	< 0.00001	-
Sumida et al[18]	Luseogliflozin	54.7 (28.2)	42.4 (26.5)	< 0.001	-

¹Change from baseline.

²Compared to placebo.

ALT: Alanine aminotransferase; CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.